查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362916

体外大肠直肠癌筛检测试市场规模、份额、趋势分析报告：按测试类型、地区和细分市场预测，2023-2030 年

In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 129 Pages | 商品交期: 2-10个工作天内

价格

体外大肠直肠癌筛检测试市场成长与趋势：

Grand View Research, Inc.最新报告显示，2023年至2030年，全球体外大肠癌筛检测试市场规模将以3.02%的年复合成长率扩张，预计2030年将达到11.2亿美元。

为因应大肠直肠恶性不断增长的趋势而增加的新型筛检模式是影响市场成长的主要要素。新开发的基因和生物标记测试的出现，如肿瘤 M2-PK粪便检验和甲基化基因测试，预计将提高肿瘤诊断模型的采用率。

恶性恶性肿瘤罹患率的增加是该领域成长的重要促进因素。例如，根据美国国家癌症中心2022年6月发布的资料，预计2022年日本将新增约1,019,000例癌症病例，其中估计新增158,200例大肠直肠癌（CRC）新病例。同样，根据澳洲癌症协会 2022 年 8 月更新的资料，预计 2022 年澳洲将诊断出 15,713 例新的结直肠癌病例，其中男性诊断为 8,300 例，女性诊断为 7,413 例。因此，恶性恶性肿瘤患病的增加预计将推动对内视镜设备的需求。

公共当局实施的各种促进筛检的措施对体外结直肠癌筛检的需求产生了积极影响。例如，Cancer.org 报导称，即使在 COVID-19大流行开始之际，加州医疗保健提供者在 2020 年 4 月和 5 月期间仍继续提供 FIT 试剂盒（粪便免疫化学检查）。儘管如此，FIT反应率仍然很高。此外，欧洲癌症界已调动资源来评估、解决和减轻 COVID-19 对筛检的负面影响。这些努力有助于满足对体外筛选测试的持续需求。

此外，市场成长预计将受到主要市场参与企业增加产品推出的推动。这些产品的发布旨在提供技术先进和创新的产品。例如，Pillar Biosciences, Inc. 于 2021 年 7 月获得 FDA核准用于 CRC 检测的 ONCO/Reveal Dx 肺癌和结肠癌检测 (O/RDx-LCCA)。

体外大肠直肠癌筛检测试市场报告亮点：

  • 依检测类型划分，2022年大便潜血试验领域占市场最大份额。
  • 在FOB检测领域中，免疫FOB ELISA检测在2022年占据很大份额。这是因为免疫测试比传统的癒创木脂 FOB粪便检验更准确。
  • 由于非侵入性筛检方法的出现，预计生物标记测试在预测期内的收益占有率将增加。
  • 与最近推出的产品（例如 ScheBo Biotech AG 的 ScheBo Oncology M2-PK粪便检验）相比，Oncology M2-PK粪便检验在 2022 年创造了最高的收益。
  • 在CRC DNA筛检测试中，面板DNA测试（一种先进的基因筛检测试）正在兴起，并贡献了最大的收益占有率。
  • 北美在 2022 年占据最大市场份额，这归因于这些产品在黑色素瘤检测临床工作流程中的高采用率。
  • 市场上营运的主要企业包括 Abbott Laboratories、Quest Diagnostics、Siemens AG、Randox Laboratories、Kyowa Medex、GeneNews 等，以获得更高的市场份额。我们始终专注于产品发布和地理扩张。
  • 2022 年 12 月，美国Guardant Health, Inc. 报告了 ECLIPSE 研究的正面结果。这项大规模研究包括 20,000 多名患者，旨在评估 Guardant Health 的血液检测在中等风险成年人中检测结直肠癌 (CRC) 的有效性。我当时就在场。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第4章检验类型业务分析

  • 体外大肠直肠癌筛检测试市场：测试类型变异分析
  • 大便潜血试验
    • 2018-2030年大便潜血试验市场
    • 瓜亚克 FOB粪便检验
    • 免疫FOB凝集试验
    • 侧流免疫FOB测试
    • 免疫 FOB ELISA 测试
  • 生物标记测试
    • 生物标记测试市场，2018-2030
    • 肿瘤M2-PK粪便检验
    • 转铁蛋白测定
    • 免疫 FOB ELISA 测试
  • CRC DNA 筛检测试
    • 2018-2030年CRC DNA筛检测试市场
    • 甲基化基因检测
    • 小组 DNA 测试

第5章区域业务分析

  • 体外大肠直肠癌筛检测试市场占有率：按地区划分，2022 年和 2030 年
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第6章竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场占有率分析
  • 公司简介/名单
    • Abbott
    • Beckman Coulter Inc
    • Eiken Chemical Co., Ltd.
    • Epigenomics
    • Sysmex Corporation
    • Siemens Healthcare GmbH
    • Quest Diagnostics Incorporated
    • OncoCyte Corporation
    • Merck KGaA
    • Immunostics Inc.
    • Kyowa Kirin Co. Ltd.
    • Randox Laboratories Ltd.
    • R-Biopharm AG
Product Code: 978-1-68038-438-3

In-vitro Colorectal Cancer Screening Tests Market Growth & Trends:

The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.12 billion by 2030, expandingat a CAGR of 3.02% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1,019,000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158,200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15,713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8,300 cases among males and 7,413 cases among females. As a result, the increasing prevalence of colorectal malignance is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

In-vitro Colorectal Cancer Screening Tests Market Report Highlights:

  • Based on test type, fecal occult blood testing segment held the largest share of the market in 2022 due to their wider usage and easy applicability by large customer base
  • Among FOB test segment, immuno-FOB ELISA test held a significant share in 2022, as immunological testing offers more accuracy than conventional guaiac FOB stool test
  • Biomarker tests are expected to gain revenue share over the forecast period due to the emergence of noninvasive screening procedures
  • Tumor M2-PK stool test generated maximum revenue in 2022 due to recent product introduction such as ScheBo Tumor M2-PK Stool Test by ScheBo Biotech AG
  • In CRC DNA screening test vertical, panel DNA tests are gaining ground as these are advanced genetic screening tests, thus contributing the maximum revenue share
  • North America held the largest share of the market in 2022, which can be attributed to high adoption rate of these products in clinical workflow for detection of melanoma
  • Key players operating in the market include Abbott Laboratories; Quest Diagnostics; Siemens AG; Randox Laboratories; Kyowa Medex; and GeneNews and are constantly focusing on product launches and geographical expansion to gain higher share in the market
  • In December 2022, Guardant Health, Inc., a company based in the United States, reported positive findings from the ECLIPSE study. This extensive study involved more than 20,000 patients and aimed to assess the effectiveness of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test type segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing incidence of colon and rectal cancers
      • 3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
      • 3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Pending investigational evidence for certain genetic screening tests
      • 3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
      • 3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Test Type Business Analysis

  • 4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
  • 4.2. Fecal Occult Blood Tests
    • 4.2.1. Fecal Occult Blood Tests Market, 2018 - 2030 (USD Million)
    • 4.2.2. Guaiac FOB Stool Test
      • 4.2.2.1. Guaiac FOB Stool Test Market, 2018 - 2030 (USD Million)
    • 4.2.3. Immuno-FOB Agglutination Test
      • 4.2.3.1. Immuno-FOB Agglutination Test Market, 2018 - 2030 (USD Million)
    • 4.2.4. Lateral Flow Immuno-FOB Test
      • 4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2018 - 2030 (USD Million)
    • 4.2.5. Immuno-FOB ELISA Test
      • 4.2.5.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.3. Biomarker Tests Market
    • 4.3.1. Biomarker Tests Market, 2018 - 2030 (USD Million)
    • 4.3.2. Tumor M2-PK Stool Test
      • 4.3.2.1. Tumor M2-PK Stool Test Market, 2018 - 2030 (USD Million)
    • 4.3.3. Transferrin Assays
      • 4.3.3.1. Transferrin Assays Market, 2018 - 2030 (USD Million)
    • 4.3.4. Immuno-FOB ELISA Test
      • 4.3.4.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.4. CRC DNA Screening Tests
    • 4.4.1. CRC DNA Screening Tests Market, 2018 - 2030 (USD Million)
    • 4.4.2. Methylated Gene Testing
      • 4.4.2.1. Methylated Gene Testing Market, 2018 - 2030 (USD Million)
    • 4.4.3. Panel DNA Tests
      • 4.4.3.1. Panel DNA Tests Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
  • 5.2. North America
    • 5.2.1. SWOT Analysis
    • 5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.3. U.S.
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.4. Canada
      • 5.2.4.1. Key Country Dynamics
      • 5.2.4.2. Target Disease Prevalence
      • 5.2.4.3. Competitive Scenario
      • 5.2.4.4. Regulatory Framework
      • 5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. SWOT Analysis
    • 5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.4. Germany
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Target Disease Prevalence
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. Regulatory Framework
      • 5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.5. France
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Target Disease Prevalence
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Regulatory Framework
      • 5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.6. Italy
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Target Disease Prevalence
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Regulatory Framework
      • 5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.7. Spain
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Target Disease Prevalence
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Regulatory Framework
      • 5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Target Disease Prevalence
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Regulatory Framework
      • 5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Target Disease Prevalence
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Regulatory Framework
      • 5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.10. Denmark
      • 5.3.10.1. Key Country Dynamics
      • 5.3.10.2. Target Disease Prevalence
      • 5.3.10.3. Competitive Scenario
      • 5.3.10.4. Regulatory Framework
      • 5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.11. Russia
      • 5.3.11.1. Key Country Dynamics
      • 5.3.11.2. Target Disease Prevalence
      • 5.3.11.3. Competitive Scenario
      • 5.3.11.4. Regulatory Framework
      • 5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.12. Netherlands
      • 5.3.12.1. Key Country Dynamics
      • 5.3.12.2. Target Disease Prevalence
      • 5.3.12.3. Competitive Scenario
      • 5.3.12.4. Regulatory Framework
      • 5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. SWOT Analysis
    • 5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.4. China
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. Regulatory Framework
      • 5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.5. India
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Target Disease Prevalence
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Regulatory Framework
      • 5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Target Disease Prevalence
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Regulatory Framework
      • 5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Target Disease Prevalence
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. Regulatory Framework
      • 5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.8. South Korea
      • 5.4.8.1. Key Country Dynamics
      • 5.4.8.2. Target Disease Prevalence
      • 5.4.8.3. Competitive Scenario
      • 5.4.8.4. Regulatory Framework
      • 5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. SWOT Analysis
    • 5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.3. Brazil
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Regulatory Framework
      • 5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.4. Mexico
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Target Disease Prevalence
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Regulatory Framework
      • 5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.5. Argentina
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Target Disease Prevalence
      • 5.5.5.3. Competitive Scenario
      • 5.5.5.4. Regulatory Framework
      • 5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. SWOT Analysis
    • 5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.3. South Africa
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Regulatory Framework
      • 5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.4. Saudi Arabia
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. Regulatory Framework
      • 5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.5. UAE
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Regulatory Framework
      • 5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.6. Kuwait
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Target Disease Prevalence
      • 5.6.6.3. Competitive Scenario
      • 5.6.6.4. Regulatory Framework
      • 5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Abbott
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Beckman Coulter Inc
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Eiken Chemical Co., Ltd.
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Epigenomics
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. Sysmex Corporation
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Siemens Healthcare GmbH
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Quest Diagnostics Incorporated
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives
    • 6.4.8. OncoCyte Corporation
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Strategic Initiatives
    • 6.4.9. Merck KGaA
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Strategic Initiatives
    • 6.4.10. Immunostics Inc.
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Strategic Initiatives
    • 6.4.11. Kyowa Kirin Co. Ltd.
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Strategic Initiatives
    • 6.4.12. Randox Laboratories Ltd.
      • 6.4.12.1. Overview
      • 6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Strategic Initiatives
    • 6.4.13. R-Biopharm AG
      • 6.4.13.1. Overview
      • 6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.13.3. Product Benchmarking
      • 6.4.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 5 North America In-vitro Colorectal Cancer Screening Tests Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 8 Canada America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 9 Europe America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 10 Europe America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 11 UK America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 12 Germany America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 13 France America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 14 Italy America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 15 Spain America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 16 Sweden America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 17 Norway America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 18 Russia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 19 Denmark America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 20 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 21 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 23 Japan America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 24 China America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 25 India America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 26 Australia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 28 South Korea America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 29 Latin America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 31 Brazil America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 32 Mexico America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 33 Argentina America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 34 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 35 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 36 South Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 37 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 38 UAE In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 39 UAE In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
  • Table 40 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 In-vitro Colorectal Cancer Screening Tests Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 In-vitro colorectal cancer screening tests market: Test type outlook and key takeaways
  • Fig. 15 In-vitro colorectal cancer screening tests market: Test type movement analysis & market share 2022 & 2030
  • Fig. 16 Global fecal occult blood tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Global guaiac FOB stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Immuno-FOB agglutination tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lateral flow immuno-FOB tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Immuno-FOB ELISA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Global biomarker tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Tumor M2-PK stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Transferrin assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global CRC DNA screening tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Methylated gene testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Panel DNA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 Regional Outlook, 2022 & 2030
  • Fig. 29 Regional Market Dashboard
  • Fig. 30 Regional Market Place: Key Takeaways
  • Fig. 31 North America, SWOT Analysis
  • Fig. 32 Europe, SWOT Analysis
  • Fig. 33 Asia Pacific, SWOT Analysis
  • Fig. 34 Latin America, SWOT Analysis
  • Fig. 35 MEA, SWOT Analysis
  • Fig. 36 North America
  • Fig. 37 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Key Country Dynamics
  • Fig. 39 U.S. America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada Key Country Dynamics
  • Fig. 41 Canada America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 43 UK Key Country Dynamics
  • Fig. 44 UK America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany Key Country Dynamics
  • Fig. 46 Germany America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 47 France Key Country Dynamics
  • Fig. 48 France America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Key Country Dynamics
  • Fig. 52 Spain America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden Key Country Dynamics
  • Fig. 54 Sweden America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway Key Country Dynamics
  • Fig. 56 Norway America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark Key Country Dynamics
  • Fig. 58 Denmark America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia Key Country Dynamics
  • Fig. 60 Russia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 61 Netherlands Key Country Dynamics
  • Fig. 62 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 64 Japan Key Country Dynamics
  • Fig. 65 Japan America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 66 China Key Country Dynamics
  • Fig. 67 China America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 68 India Key Country Dynamics
  • Fig. 69 India America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia Key Country Dynamics
  • Fig. 71 Australia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand Key Country Dynamics
  • Fig. 73 Thailand America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea Key Country Dynamics
  • Fig. 75 South Korea America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil Key Country Dynamics
  • Fig. 78 Brazil America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico Key Country Dynamics
  • Fig. 80 Mexico America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina Key Country Dynamics
  • Fig. 82 Argentina America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa Key Country Dynamics
  • Fig. 85 South Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia Key Country Dynamics
  • Fig. 87 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 88 UAE Key Country Dynamics
  • Fig. 89 UAE America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait Key Country Dynamics
  • Fig. 91 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 92 Strategy Mapping